Australia markets closed

Sage Therapeutics, Inc. (SAGE)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
11.18-0.52 (-4.44%)
At close: 04:00PM EDT
11.25 +0.07 (+0.63%)
After hours: 07:12PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 672.84M
Enterprise value -40.87M
Trailing P/E N/A
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)7.36
Price/book (mrq)0.95
Enterprise value/revenue N/A
Enterprise value/EBITDA N/A

Trading information

Stock price history

Beta (5Y monthly) 0.91
52-week change 3-78.68%
S&P500 52-week change 328.04%
52-week high 359.99
52-week low 310.92
50-day moving average 315.61
200-day moving average 319.96

Share statistics

Avg vol (3-month) 31.05M
Avg vol (10-day) 31.28M
Shares outstanding 560.18M
Implied shares outstanding 660.98M
Float 847.52M
% held by insiders 112.47%
% held by institutions 199.61%
Shares short (30 Apr 2024) 48.15M
Short ratio (30 Apr 2024) 46.73
Short % of float (30 Apr 2024) 415.38%
Short % of shares outstanding (30 Apr 2024) 413.55%
Shares short (prior month 28 Mar 2024) 48.6M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 0.00%
Operating margin (ttm)-1,489.18%

Management effectiveness

Return on assets (ttm)-31.98%
Return on equity (ttm)-54.72%

Income statement

Revenue (ttm)91.06M
Revenue per share (ttm)1.52
Quarterly revenue growth (yoy)139.90%
Gross profit (ttm)N/A
EBITDA -507.26M
Net income avi to common (ttm)-503.14M
Diluted EPS (ttm)-8.39
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)717.01M
Total cash per share (mrq)11.91
Total debt (mrq)3.31M
Total debt/equity (mrq)0.47%
Current ratio (mrq)12.22
Book value per share (mrq)11.73

Cash flow statement

Operating cash flow (ttm)-424.74M
Levered free cash flow (ttm)-232.9M